Risk of Lymphohematologic Malignancies Increased in Patients With Chronic Plaque Psoriasis

The risk of lymphohematologic malignancies (LHM) is increased in patients with chronic plaque psoriasis, according to a recent study published in Journal of the American Academy of Dermatology.

Researchers aimed to investigate the risk of LHM in patients with psoriasis according to the best evidence gathered from a systematic review and meta-analysis of observational cohort studies. The studies assessed the association of psoriasis with different LHMs performed. In total, 25 observational studies, including 2,501,652 patients, were analyzed.

Patients with severe plaque psoriasis had a significantly increased risk for LHM (hazard ratio [HR], 1.55; 1.24-2.94) and lymphoma compared with the general population. An increased risk was also found for Hodgkin lymphoma (HR, 1.71; 1.27-2.30), non-Hodgkin lymphoma (HR, 1.27; 1.08-1.50), multiple myeloma (HR, 1.32; 1.03-1.69) and leukemia (HR, 1.28; 1.00-1.65). Cutaneous T cell lymphoma (CTCL) risk was greatly increased in patients with psoriasis.

“The increased risk of LHM, particularly CTCL, in patients with psoriasis could be related to the exposure to systemic immunosuppressive therapies, comorbidities and sustained immune activation, particularly in the skin,” concluded the study authors.

Reference
Bellinato F, Gisondi P, Girolomoni G. Risk of lympho-haematological malignancies in patients with chronic plaque psoriasis: a systematic review with meta-analysis. J Am Acad Dermatol. 2021;S0190-9622(21)02212-X. doi:10.1016/j.jaad.2021.07.050